Elevation Oncology Stock Filter Stocks by Fundamentals
| ELEV Stock | USD 0.38 0.01 2.70% |
Fundamental analysis of Elevation Oncology allows traders to better anticipate movements in Elevation Oncology's stock price by examining its financial health and performance throughout various phases of its business cycle.
Elevation | Shares Owned by Institutions | Build AI portfolio with Elevation Stock |
Elevation Oncology Institutional Holders
Institutional Holdings refers to the ownership stake in Elevation Oncology that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Elevation Oncology's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Elevation Oncology's value.| Shares | Sphera Funds Management Ltd. | 2025-03-31 | 358.6 K | Ameriprise Financial Inc | 2025-03-31 | 298.8 K | Palumbo Wealth Management Llc | 2025-03-31 | 278 K | Schonfeld Strategic Advisors Llc | 2025-03-31 | 275.4 K | Acadian Asset Management Llc | 2025-03-31 | 197.1 K | Two Sigma Investments Llc | 2025-03-31 | 194 K | Two Sigma Advisers, Llc | 2025-03-31 | 193.1 K | Deutsche Bank Ag | 2025-03-31 | 185.6 K | Boothbay Fund Management, Llc | 2025-03-31 | 183.5 K | Bml Capital Management Llc | 2025-03-31 | 5.9 M | Tang Capital Management Llc | 2025-03-31 | 4.8 M |
Elevation Fundamentals
| Return On Equity | -0.78 | ||||
| Return On Asset | -0.3 | ||||
| Current Valuation | (27.17 M) | ||||
| Shares Outstanding | 59.25 M | ||||
| Shares Owned By Insiders | 0.35 % | ||||
| Shares Owned By Institutions | 57.31 % | ||||
| Number Of Shares Shorted | 2.08 M | ||||
| Price To Earning | 0.16 X | ||||
| Price To Book | 0.48 X | ||||
| EBITDA | (44.7 M) | ||||
| Net Income | (44.48 M) | ||||
| Cash And Equivalents | 122.54 M | ||||
| Cash Per Share | 5.26 X | ||||
| Total Debt | 31.13 M | ||||
| Current Ratio | 6.48 X | ||||
| Book Value Per Share | 0.79 X | ||||
| Cash Flow From Operations | (36.36 M) | ||||
| Short Ratio | 1.51 X | ||||
| Earnings Per Share | (0.81) X | ||||
| Target Price | 0.52 | ||||
| Number Of Employees | 34 | ||||
| Beta | 1.45 | ||||
| Market Capitalization | 22.23 M | ||||
| Total Asset | 95.63 M | ||||
| Retained Earnings | (240.46 M) | ||||
| Working Capital | 90.26 M | ||||
| Net Asset | 95.63 M |
About Elevation Oncology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Elevation Oncology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Elevation Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Elevation Oncology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Elevation Stock Analysis
When running Elevation Oncology's price analysis, check to measure Elevation Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elevation Oncology is operating at the current time. Most of Elevation Oncology's value examination focuses on studying past and present price action to predict the probability of Elevation Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elevation Oncology's price. Additionally, you may evaluate how the addition of Elevation Oncology to your portfolios can decrease your overall portfolio volatility.